Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3
Clin. transl. oncol. (Print)
; 24(3): 517-531, marzo 2022.
Article
in English
| IBECS
| ID: ibc-203546
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
BackgroundPancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignant tumors of the digestive system. Many patients are diagnosed at an advanced stage and lose eligibility for surgery. Moreover, there are few effective methods for treating pancreatic ductal cell carcinoma. Increasing attention has been given to microRNAs (miRNAs) and their regulatory roles in tumor progression. In this study, we investigated the effects of exosomes extracted from human umbilical cord mesenchymal stem cells (HUCMSCs) carrying hsa-miRNA-128-3p on pancreatic cancer cells.MethodsBased on existing experimental and database information, we selected Galectin-3, which is associated with pancreatic cancer, and the corresponding upstream hsa-miRNA-128-3p. We extracted HUCMSCs from a fresh umbilical cord, hsa-miRNA-128-3p was transfected into HUCMSCs, and exosomes containing hsa-miRNA-128-3p were extracted and collected. The effect of exosomes rich in hsa-miRNA-128-3p on pancreatic cancer cells was analyzed.ResultsThe expression of Galectin-3 in normal pancreatic duct epithelial cells was significantly lower than that in PDAC cell lines. We successfully extracted HUCMSCs from the umbilical cord and transfected hsa-miRNA-128-3p into HUCMSCs. Then we demonstrated that HUCMSC-derived exosomes with hsa-miRNA-128-3p could suppress the proliferation, invasion, and migration of PANC-1 cells in vitro by targeting Galectin-3.ConclusionHsa-miRNA-128-3p could be considered as a potential therapy for pancreatic cancer. We provided a new idea for targeted therapy of PDAC.
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Umbilical Cord
/
Carcinoma, Pancreatic Ductal
/
Galectin 3
/
Exosomes
/
Mesenchymal Stem Cells
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2022
Document type:
Article
Institution/Affiliation country:
Affiliated Hospital and Medical School of Nantong University/China
/
Affiliated Hospital of Nantong University/China
/
Blood Center of Jiangsu Province/China
/
Medical School of Nantong University Oral Medicine/China
/
Second Peoples Hospital of Nantong/China